Watch the exceptional presentations, plus the Q&A panel discussions, on demand from Symposium 2023!

Truly Comprehensive, Genome-wide Detection of Causative Chromosomal Aberrations

Structural variants (SVs) make up most of human genomic variation and are implicated in reproductive health issues and genetic diseases, such as infertility and miscarriages, neurodevelopmental delay, and rare diseases. The “gold standard” techniques used to identify pathogenic SVs linked to these diseases, including cytogenetic and molecular methods, often fall short.

Current approaches do not detect all potential SVs implicated in DD/ID etiology.11-12 Leverage the power of OGM to achieve results that correlate highly to traditional cytogenetic methods while revealing new pathogenic SVs in some cases where array and sequencing were unsuccessful.

OGM’s comprehensive SV detection empowers labs to increase their chances of finding pathogenic SVs that lead to rare genetic diseases.13-15

OGM is a tool that helps researchers better understand the underlying genetic etiology of recurrent miscarriage, infertility, and pregnancy abnormalities, including the ability to resolve some cryptic aberrations not detected with traditional methods.16-19

What happens when you combine NGS with OGM?

When OGM is added to the mix, you get better detection of insertions, deletions, duplications, translocations, inversions, and repeat expansions. Learn more about how OGM works

Previous studies have shown that a substantial portion of SVs detected by OGM are not detected by sequencing methods.20-22

Combine NGS and OGM to achieve a comprehensive view of the genome, across all variant types and sizes.

Overall, OGM maximizes detection providing an increase in pathogenic findings across genetic disease and cancer.

Case Studies

Review these genetic disease case studies to learn how OGM finds variants other technologies cannot.
Download

“OGM allows next generation cytogenetics and enables the identification of hidden structural variants as a cause of rare diseases.”

Alexander Hoischen, PhD
Radboud UMC, The Netherlands

“OGM helps to resolve the genetic basis of immunodeficiencies important for receiving specific therapy.”

Dr. Doris Steinemann
Hannover Human Genetics, Hannover, Germany

“OGM reveals more of what matters: more clinically relevant SVs leading to higher success rates and resolution of unsolved cases.”

Dr. Laïla El-Khattabi
Hôpitaux de Paris (AP-HP)-Université de Paris Paris, France

LEARN HOW OGM BENEFITS CLINICAL GENETIC DISEASE RESEARCH

OGM find new candidate genes

In a newborn with Congenital Diaphragmatic Hernia (CDH), a severe developmental disorder affecting the diaphragm, lungs and sometimes heart, OGM detected two adjacent duplications, one direct and one inverted. OGM revealed a much more complex architecture than could be inferred from microarray data and identified several additional candidate genes for CDH.24

OGM identifies new variants in known genes

In a subject with Duchenne Muscular Dystrophy (DMD), a 420 kbp segment from chromosome 15 was duplicated in an inverted orientation in intron 44 of the Dystrophin gene. This insertion was not detected by NGS, and while chromosomal microarray can detect the duplication, its location and, therefore, implication in DMD could not be determined.25

OGM reveals repeat expansions

In a single postmortem brain sample from an ALS subject, OGM detected a highly mosaic range of expansions of the C9orf72 GGGGCC repeat, ranging from the reference allele (not shown) to a 32 kbp expansion. No modern technology has been capable of spanning and measuring these large C9orf72 repeat expansions.26

OGM detects FSHD1

Facioscapulohumeral Muscular Dystrophy (FSHD1) is a common form of muscular dystrophy with an extremely complex genotype. Correct genotyping requires the accurate sizing of a very large repeat region in the subtelomeric region of chromosome 4, a correct determining of the pathogenic vs non-pathogenic allele, and the distinction between the chromosome 4 repeat and an almost identical repeat on chromosome 10 not related to the disease. A team from the University of Iowa published the largest clinical research study to date evaluating OGM for FSHD1. The study, published in the Journal of Molecular Diagnostics, concluded that OGM can be performed more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis.27

Learn More About OGM

Read about what structural variations are and why they matter.

Learn More

See how OGM reveals structural variation in a way that has never been done before.

Learn More

Find the latest research in our Publications Library.

Learn More

Sign up to receive the latest evidence on OGM for genetic disease applications.

Sign Me Up!

RELATED MATERIALS

title SOURCE Authors
ATTCT and ATTCC repeat expansions in the ATXN10 gene affect disease penetrance of spinocerebellar ataxia type 10 October 13, 2022

C Alejandra Morato Torres, Faria Zafar, Yu-Chih Tsai, Jocelyn Palafox Vazquez, Michael D Gallagher, Ian McLaughlin, Karl Hong, Jill Lai, Joyce Lee, Amanda Chirino-Perez, Angel Omar Romero-Molina, Francisco Torres, Juan Fernandez-Ruiz, Tetsuo Ashizawa, Janet Ziegle, Francisco Javier Jiménez Gil, Birgitt Schüle

The snapdragon genomes reveal the evolutionary dynamics of the S locus supergene October 10, 2022

Sihui Zhu, Yu’e Zhang, Lucy Copsey, Dongfeng Zheng, Enrico Coen, Yongbiao Xue, Qianqian Han

Molecular and genetic mechanisms conferring dissolution of dioecy in Diospyros oleifera Cheng October 9, 2022

Peng Sun Jr., Soichiro Nishiyama Jr., Huawei Li Jr., Yini Mai Jr., Weijuan Han Jr., Yujing Suo Jr., Chengzhi Liang Sr., Huilong Du Jr., Songfeng Diao Jr., Yiru Wang Jr., Jiaying Yuan Jr., Yue Zhang Jr., Ryutaro Tao Sr., Fangdong Li Sr., Jianmin Fu Sr.

  1. Zarocostas J. Serious birth defects kill at least three million children a year. BMJ. 2006;332:256. doi: 10.1136/bmj.332.7536.256-b
  2. Tsui et al. Blood Cancer J. 2020. PMID 33077814.
  3. Nimer. Best Pract Res Clin Haematol. 2008. PMID: 18342811.
  4. Walker et al. Expert Rev Hematol. 2012. PMID: 23146058.
  5. Graessner et al. Eur J Hum Genet. 2021. PMID: 34140650.
  6. Seo et al. Mol Med. 2022. PMID: 35346031.
  7. Clark, M. M. et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. npj Genom. Med. 3, 1–10 (2018).
  8. Stavropoulos, D. J. et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. Genomic Med. 1, 15012 (2016).
  9. Savatt JM, Myers SM. Genetic testing in neurodevelopmental disorders. Front Pediatr. 2021, 9:526779
  10. Álvarez-Mora MI, Sánchez A, Rodríguez-Revenga L, Corominas J, Rabionet R, Puig S, Madrigal I. Diagnostic yield of next‑ generation sequencing in 87 families with neurodevelopmental disorders. Orphanet Journal of Rare Disease; 2022, 17:60
  11. Mantere T, et al. Optical genome mapping enables constitutional chromosomal aberration detection. Am J Hum Genet. 2021 Aug 5;108(8):1409-1422. doi: 10.1016/j.ajhg.2021.05.012. Epub 2021 Jul 7. PMID: 34237280; PMCID: PMC8387289
  12. Iqbal et al. Multi-site Technical Performance and Concordance of Optical Genome Mapping: Constitutional Postnatal Study for SV, CNV, and Repeat Array Analysis. MedRxiv 2021.12.27.21268432; doi: https://doi.org/10.1101/2021.12.27.21268432
  13. Shieh, J.T., Penon-Portmann, M., Wong, K.H.Y. et al. Application of full-genome analysis to diagnose rare monogenic disorders. npj Genom. Med. 6, 77 (2021). https://doi.org/10.1038/s41525-021-00241-5
  14. Stence AA, et al. Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy. J Mol Diagn. 2021 Nov;23(11):1506-1514. doi: 10.1016/j.jmoldx.2021.07.021. Epub 2021 Aug 9. PMID: 34384893; PMCID: PMC8647435.
  15. Dremsek P, et al. Optical Genome Mapping in Routine Human Genetic Diagnostics-Its Advantages and Limitations. Genes (Basel). 2021 Dec 8;12(12):1958. doi: 10.3390/genes12121958. PMID: 34946907; PMCID: PMC8701374.
  16. Yang, Y., Hao, W. Identification of a familial complex chromosomal rearrangement by optical genome mapping. Mol Cytogenet 15, 41 (2022). https://doi.org/10.1186/s13039-022-00619-9
  17. Zhang S, Pei Z, Lei C, et al. Detection of cryptic balanced chromosomal rearrangements using high-resolution optical genome mapping. Journal of Medical Genetics Published Online First: 16 June 2022. doi: 10.1136/jmedgenet-2022-108553
  18. Sahajpal NS, et al. Optical Genome Mapping as a Next-Generation Cytogenomic Tool for Detection of Structural and Copy Number Variations for Prenatal Genomic Analyses. Genes (Basel). 2021 Mar 11;12(3):398. doi: 10.3390/genes12030398. PMID: 33799648; PMCID: PMC8001299.
  19. Dai P, Zhu X, Pei Y, Chen P, Li J, Gao Z, Liang Y, Kong X. Evaluation of optical genome mapping for detecting chromosomal translocation in clinical cytogenetics. Mol Genet Genomic Med. 2022 Jun;10(6):e1936. doi: 10.1002/mgg3.1936. Epub 2022 Apr 6. PMID: 35384386; PMCID: PMC9184658.
  20. Ebert P, et al. Haplotype-resolved diverse human genomes and integrated analysis of structural variation. Science. 2021 Apr 2;372(6537):eabf7117. doi: 10.1126/science.abf7117.
  21. Bayard Q, et al. Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma. Cancer Res. 2022 Apr 15;82(8):1470-1481. doi: 10.1158/0008-5472.CAN-21-3665.
  22. Chaisson, M.J.P., Sanders, A.D., Zhao, X. et al. Multi-platform discovery of haplotype-resolved structural variation in human genomes. Nat Commun 10, 1784 (2019). https://doi.org/10.1038/s41467-018-08148-z
  23. High S. Advanced analysis of risk loci in congenital disorders using Bionano optical genome mapping. ASHG Bionano Symposium. 2019. https://bionanogenomics.com/videos/ashg-2019-series-dr-frances-high/
  24. Barseghyan H. Bionano mapping for evaluation of structural variants in genetic diseases. ASHG Bionano Symposium. 2019.
  25. Ebbert MTW. Resolving complex genomic haplotypes in neurodegenerative disorders using Bionano Genomics Saphyr System. ASHG Bionano Symposium. 2019.
  26. Stence AA, Thomason JG, Pruessner JA, et al. Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy. J Mol Diagn. 2021;23(11):1506-1514. doi:10.1016/j.jmoldx.2021.07.021